Basiliximab
- Generic Name
- Basiliximab
- Brand Names
- Simulect
- Drug Type
- Biotech
- CAS Number
- 179045-86-4
- Unique Ingredient Identifier
- 9927MT646M
- Background
A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha.
- Indication
For prophylactic treatment of kidney transplant rejection
- Associated Conditions
- Rejection Acute Renal
Efficacy and Safety of Basiliximab in Hepatitis C Virus Positive Patients Undergoing Liver Transplantation
- Conditions
- Liver Transplant
- First Posted Date
- 2005-10-14
- Last Posted Date
- 2010-09-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 194
- Registration Number
- NCT00238901
An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.
- Conditions
- Acute Renal Allograft RejectionCadaveric Donor Renal TransplantationInduction Therapy
- Interventions
- Biological: Thymoglobulin [Anti-thymocyte Globulin (rabbit)]
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 240
- Registration Number
- NCT00235300
- Locations
- 🇺🇸
UCLA School of Medicine, Los Angeles, California, United States
🇺🇸Florida Hospital Medical Center and Translife, Orlando, Florida, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans in Lung Transplant
- Conditions
- Alpha-1 Antitrypsan DeficiencyCOPDEmphysema
- Interventions
- Other: placebo
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-05-04
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 22
- Registration Number
- NCT00188825
- Locations
- 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients
- Conditions
- Organ Transplantation, Renal Transplantation
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 114
- Registration Number
- NCT00154284
Efficacy and Safety of Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients Avoiding Intraoperative Steroids
- Conditions
- Liver TransplantationInfection
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2011-09-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 77
- Registration Number
- NCT00149890
- Locations
- 🇩🇪
Novartis Investigational Site, Various Cities, Germany
Cyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients
- Conditions
- Liver Transplant
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 171
- Registration Number
- NCT00149994
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients
- Conditions
- Kidney Transplantation
- Interventions
- First Posted Date
- 2005-06-08
- Last Posted Date
- 2011-08-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 501
- Registration Number
- NCT00113269
Steroid Withdrawal in Pediatric Kidney Transplant Recipients
- Conditions
- End-Stage Renal Disease
- Interventions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2016-10-21
- Target Recruit Count
- 274
- Registration Number
- NCT00023244
- Locations
- 🇺🇸
University of Florida Health Science Center, Jacksonville, Florida, United States
🇺🇸The Children's Hospital of Buffalo, Buffalo, New York, United States
🇺🇸Westchester Medical Center, Valhalla, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.